Skip to content
Company Analysis

BioAge Labs, Inc. BIOA

A comprehensive view of key metrics, scores, and financial health for BioAge Labs, Inc.

Overview of BioAge Labs, Inc.

BIOA NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
BioAge Labs, Inc. (BIOA), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $21.92, about 0.0% overvalued vs fair value, +395.9% 1Y return, ranked 768/1145 in sector.
Metrics ROE -27.1%
USD 21.92
-0.09%
(Delayed)
• Vol 90d: 80.1%
52-Week Range
Market Cap
$1.11B
Enterprise Value
$727.27M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 76%
Confidence: 80%
Updated: Jul 5
Top Beats
No strong beats yet

Quick Facts

Website https://bioagelabs.com
HQ Richmond, CA
Employees 62
Fiscal year Dec 31

Next Events

Earnings Aug 6 Estimated

Fair Value Snapshot

Bear Base Bull
$-2
$-2
$-2
Current: $21.92

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$9.0M
R&D Expense
$74.0M
25.3%%
Operating Income (EBIT)
$-79.9M
-16.2%%
Operating Cash Flow
$-81.6M
-58.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
822.3%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating BioAge Labs, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
21
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
10
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 63% Coverage
Trade-Off Triangle Visualization A ternary plot showing BIOA's balance between Growth (32.9%), Profitability (15.3%), and Safety (51.8%). Growth 33% Safety 52% Profitability 15%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

- vs peers
-
Key Signals
EPS Growth YoY 66.2% 62p
Strengths
  • Current Ratio in top 20% of peers (14.24, 97th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

15th percentile vs peers
15
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

52th percentile vs peers
52
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for BioAge Labs, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-2.40
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000